VEGFA and pancreatic neuroendocrine tumor: Highlighting CXCL14’s pleotropic functions, Rivera et al. found that CXCL14 production by myeloid cells in mouse Rip1Tag2 pancreatic neuroendocrine tumors (PNETs) actually sensitized tumors to vascular endothelial growth factor (VEGF) therapy [119].